---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006001"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:30:12.846041+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oragenics enters $5M ATM offering with Ladenburg Thalmann; cash $11.4M, runway through Q3 2023

## Summary
- Entered ATM sales agreement with Ladenburg Thalmann to sell up to $5M of common stock; 3% commission.
- Cash and equivalents expected ~$11.4M as of Dec 31, 2022; sufficient to fund operations through Q3 2023.
- Reverse stock split (1-for-60) completed Jan 20, 2023; post-split shares outstanding ~2.02M.
- Plans to file IND for NT-CoV2-1 (Terra CoV-1) in US or Canada and start Phase 1 in H2 2023.
- Proceeds to fund pre-clinical development of SARS-CoV-2 vaccine and lantibiotics program.

## SEC filing metadata
- accession: 0001493152-23-006001
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/0001493152-23-006001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006001
- JSON: https://secwatch.observer/filing/0001493152-23-006001.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006001.txt

## Key facts
- Material Agreements
  ORAGENICS INC entered into Sales Agreement with Ladenburg Thalmann & Co. Inc. valued at $5,000,000 (effective 2023-02-24).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Value: $5,000,000
  - Effective: 2023-02-24
  source text: On February 24, 2023, Oragenics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Agent”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock (the “Shares”), depending on market demand, with the Agent acting as the sales agent or principal (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/0001493152-23-006001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.